The vaccine was developed by scientists at the Oxford Vaccine Group and Pandemic Sciences Institute. On Friday, the University of Oxford announced that the first volunteer has been successfully vaccinated in the world’s first clinical trial of a vaccine designed to protect against Bundibugyo ebolavirus. The vaccine was developed by scientists at the university’s Oxford Vaccine Group and Pandemic Sciences Institute. Now, the world’s first vaccine candidate designed specifically to protect against Bundibugyo ebolavirus has entered human trials. Subject to regulatory approval, preparations are also underway for further clinical studies of the vaccine with partners in Uganda, according to the university.